Overview

PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide

Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore whether the GLP-1 receptor agonist exenatide, may prevent glucocorticoid-induced glucometabolic abnormalities and beta-cell dysfunction in healthy subjects.
Phase:
N/A
Details
Lead Sponsor:
VU University Medical Center
Collaborator:
National Research Council, Institute of Biomedical Engineering
Treatments:
Exenatide
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate